Charles River Laboratories International, Inc.
CRL
$155.46
$2.801.83%
NYSE
| 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.85% | -0.92% | -1.21% | -2.16% | -1.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.85% | -0.92% | -1.21% | -2.16% | -1.92% |
| Cost of Revenue | -1.18% | 0.38% | -0.36% | 0.01% | 0.97% |
| Gross Profit | -0.23% | -3.26% | -2.74% | -6.02% | -6.92% |
| SG&A Expenses | 0.58% | 0.59% | 4.40% | -2.79% | -2.21% |
| Depreciation & Amortization | 36.75% | 2.82% | 5.37% | 3.25% | -6.96% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.57% | 0.51% | 0.82% | -0.46% | -0.02% |
| Operating Income | -9.79% | -9.18% | -12.58% | -11.87% | -12.41% |
| Income Before Tax | -206.86% | -104.28% | -103.36% | -94.52% | -83.98% |
| Income Tax Expenses | -37.10% | -36.63% | -50.57% | -45.71% | -32.79% |
| Earnings from Continuing Operations | -662.11% | -118.60% | -114.56% | -105.17% | -94.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 29.57% | 36.83% | 48.55% | 69.36% | 46.26% |
| Net Income | -750.08% | -119.42% | -115.18% | -105.69% | -95.32% |
| EBIT | -9.79% | -9.18% | -12.58% | -11.87% | -12.41% |
| EBITDA | -0.04% | -8.10% | -1.62% | -7.60% | -7.20% |
| EPS Basic | -1,803.99% | -119.22% | -115.64% | -107.41% | -98.13% |
| Normalized Basic EPS | -8.00% | -19.14% | -17.63% | -17.63% | -15.04% |
| EPS Diluted | -2,050.69% | -119.49% | -115.90% | -107.62% | -98.35% |
| Normalized Diluted EPS | -7.87% | -18.96% | -17.38% | -17.46% | -14.95% |
| Average Basic Shares Outstanding | -3.53% | -2.68% | -1.57% | -0.24% | 0.30% |
| Average Diluted Shares Outstanding | -3.65% | -2.95% | -1.91% | -0.51% | 0.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |